List view / Grid view
24 October 2011 | By Merck
Merck announced results from two 26-week investigational Phase III clinical studies...
22 October 2011 | By Biogen Idec
Biogen Idec and Abbott announced additional results from the SELECT Phase 2b trial...
22 October 2011 | By Sanofi
New results from the CARE-MS I trial...
21 October 2011 | By Janssen Pharmaceuticals Inc.
New HIV data to be presented at EACS 2011...
21 October 2011 | By Biogen Idec
Phase 3 clinical trial demonstrated significant clinical effects...
21 October 2011 | By ICON plc
ICON has announced it has received a contract award from the Foundation for the National Institutes of Health (FNIH)...
21 October 2011 | By Johnson and Johnson
New data presented at EADV...
21 October 2011 | By AstraZeneca
AstraZeneca will present key results from health economics sub-studies...
20 October 2011 | By Roche
Phase III trials underway to investigate ocrelizumab in two forms of MS...
19 October 2011 | By Abbott
Abbott plans to separate into two companies, one in diversified medical products & the other in research-based pharmaceuticals...
19 October 2011 | By Amgen
Amgen appoints Anthony Hooper as Executive VP, Global Commercial Operations...
19 October 2011 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company announced a series of related changes within its Senior Management Team...
19 October 2011 | By Eli Lilly and Company
FDA has approved a new use for BYETTA® (exenatide) injection....
18 October 2011 | By GlaxoSmithKline
RTS,S* reduces the risk of malaria by half...
18 October 2011 | By AstraZeneca
ceftazidime/avibactam (CAZ-AVI) will enter phase III trials...
